Zymeworks (ZYME) EPS (Weighted Average and Diluted) (2021 - 2026)
Zymeworks' (ZYME) quarterly EPS (Weighted Average and Diluted) came in at -$0.59 in Q1 2026, down 96.67% year-on-year from -$17.7 in Q1 2025, and down 7.27% quarter-over-quarter from -$0.55 in Q4 2025.
Zymeworks (ZYME) EPS (Weighted Average and Diluted) (2021 - 2026) Analysis & Trends
Zymeworks has disclosed EPS (Weighted Average and Diluted) across 6 years of filings, most recently posting -$0.59 for Q1 2026.
- EPS (Weighted Average and Diluted) for Q1 2026 came in at -$0.59, down 96.67% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.37 (up 8.67% YoY), and the FY2025 annual result was -$1.08, up 33.33% from the prior year.
- EPS (Weighted Average and Diluted) came in at -$0.59 for Q1 2026 at Zymeworks, down from -$0.55 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $4.76 in Q4 2022 to a low of -$1.19 in Q1 2022.
- The 5-year median for EPS (Weighted Average and Diluted) is -$0.41 (2023), against an average of -$0.18.
- Across the five-year window, EPS (Weighted Average and Diluted) jumped 601.05% in 2022 and tumbled 103.99% in 2023, its largest moves.
- Zymeworks' EPS (Weighted Average and Diluted) stood at $4.76 in 2022, then sank by 103.99% to -$0.19 in 2023, then sank by 68.42% to -$0.32 in 2024, then tumbled by 71.87% to -$0.55 in 2025, then slipped by 7.27% to -$0.59 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.59 (Q1 2026), -$0.55 (Q4 2025), and -$0.26 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Zymeworks | 1.73 Bn | 1.36 Bn | - | -0.59 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.59 |
| Dec 31, 2025 | -0.55 |
| Sep 30, 2025 | -0.26 |
| Jun 30, 2025 | 0.03 |
| Mar 31, 2025 | -0.30 |
| Dec 31, 2024 | -0.32 |
| Sep 30, 2024 | -0.39 |
| Jun 30, 2024 | -0.49 |
| Mar 31, 2024 | -0.42 |
| Dec 31, 2023 | -0.19 |
| Sep 30, 2023 | -0.41 |
| Jun 30, 2023 | -0.76 |
| Mar 31, 2023 | -0.37 |
| Dec 31, 2022 | 4.76 |
| Sep 30, 2022 | -0.72 |
| Jun 30, 2022 | -0.97 |
| Mar 31, 2022 | -1.19 |
| Dec 31, 2021 | -0.95 |
| Sep 30, 2021 | -1.25 |